Role of cytokines in postmenopausal bone loss
- 57 Downloads
It is increasingly recognized that changes in cytokine activity are involved in the pathophysiology of postmenopausal bone loss in many ways. Estrogen may affect skeletal cytokine activity by diverse mechanisms such as direct interference with cytokine gene transcription, regulation of major signaling molecules, changes in lymphocyte function, and central effects on the hypothalamic-pituitary-adrenal axis. This article summarizes our current knowledge of these interactions and discusses the possible implications with respect to the prevention and treatment of postmenopausal osteoporosis.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 13.Roggia C, Gao Y, Cenci S, et al.: Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001, 98:13960–13965. This paper demonstrates the importance of TNF-α-producing T cells for bone loss in ovariectomized mice.PubMedCrossRefGoogle Scholar
- 18.Beishuizen A, Thijs LG: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003, 9:3–24. This recent review gives a comprehensive summary of the relationship between the HPA axis and inflammation. The potential relevance of this pathway with respect to postmenopausal bone loss is just beginning to be explored.PubMedCrossRefGoogle Scholar
- 22.Cuzzocrea S, Mazzon E, Dugo L, et al.: Inducible nitric oxide synthase mediates bone loss in ovariectomized mice. Endocrinology 2003, 144:1098–1107. This paper convincingly demonstrates an essential role of iNOS in the pathogenesis of cytokine increases and bone loss in ovariectomized mice.PubMedCrossRefGoogle Scholar
- 27.Weitzmann MN, Roggia C, Toraldo G, et al.: Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002, 110:1643–1650. This is one of the most recent papers on the essential role of a particular cytokine in ovariectomy-induced bone loss.PubMedCrossRefGoogle Scholar
- 28.Lindberg MK, Movérare S, Eriksson A-L, et al.: Identification of estrogen-regulated genes of potential importance for the regulation of trabecular bone density. J Bone Miner Res 2002, 17:2183–2195. This paper gives an array-based analysis of changes in gene expression in mouse bone tissue with ovariectomy. It also gives an impression of the multitude of components in the cytokine network whose expression is altered with estrogen deficiency.PubMedCrossRefGoogle Scholar
- 29.Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al.: Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001, 86:2032–2042. This paper provides evidence from an epidemiologic study that circulating IL-6 may be a major predictor of early postmenopausal bone loss.PubMedCrossRefGoogle Scholar
- 31.Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL: Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women. J Clin Endocrinol Metab 2002, 87:2892–2898. Infusion of PTH caused an exaggerated increase in circulating concentrations of IL-6 and sIL-6r in estrogen-deficient postmenopausal women, compared with estrogen-replete women, suggesting that PTH may be an important determinant of IL-6 activity after menopause.PubMedCrossRefGoogle Scholar
- 33.Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321–333. The results of this landslide study have tremendously changed our perception on the risks and benefits of hormone therapy in postmenopausal women.CrossRefGoogle Scholar
- 38.Demis E, Roux C, Breban M, Dougados M: Infliximab in spondylarthropathy-influence on bone density. Clin Exp Rheumatol 2002, 28(Suppl:20):S185–186.Google Scholar